[go: up one dir, main page]

NO20011183L - 4,4-biarylpiperidinderivater med opoid reseptoraktivitet - Google Patents

4,4-biarylpiperidinderivater med opoid reseptoraktivitet

Info

Publication number
NO20011183L
NO20011183L NO20011183A NO20011183A NO20011183L NO 20011183 L NO20011183 L NO 20011183L NO 20011183 A NO20011183 A NO 20011183A NO 20011183 A NO20011183 A NO 20011183A NO 20011183 L NO20011183 L NO 20011183L
Authority
NO
Norway
Prior art keywords
receptor activity
opoid receptor
biarylpiperidine
derivatives
biarylpiperidine derivatives
Prior art date
Application number
NO20011183A
Other languages
English (en)
Norwegian (no)
Other versions
NO20011183D0 (no
Inventor
Spiros Liras
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20011183D0 publication Critical patent/NO20011183D0/no
Publication of NO20011183L publication Critical patent/NO20011183L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20011183A 1998-09-09 2001-03-08 4,4-biarylpiperidinderivater med opoid reseptoraktivitet NO20011183L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9956598P 1998-09-09 1998-09-09
PCT/IB1999/001512 WO2000014066A1 (fr) 1998-09-09 1999-09-06 Derives de 4,4-biarylpiperidine possedant une activite de recepteur opioide

Publications (2)

Publication Number Publication Date
NO20011183D0 NO20011183D0 (no) 2001-03-08
NO20011183L true NO20011183L (no) 2001-05-04

Family

ID=22275622

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011183A NO20011183L (no) 1998-09-09 2001-03-08 4,4-biarylpiperidinderivater med opoid reseptoraktivitet

Country Status (41)

Country Link
US (2) US6720336B2 (fr)
EP (1) EP1112255B1 (fr)
JP (1) JP2002524445A (fr)
KR (1) KR20010075024A (fr)
CN (1) CN1316993A (fr)
AP (1) AP2001002088A0 (fr)
AR (1) AR022376A1 (fr)
AT (1) ATE312819T1 (fr)
AU (1) AU749096B2 (fr)
BG (1) BG105411A (fr)
BR (1) BR9913512A (fr)
CA (1) CA2343236C (fr)
CO (1) CO5170416A1 (fr)
CZ (1) CZ2001850A3 (fr)
DE (1) DE69928945T2 (fr)
EA (1) EA200100203A1 (fr)
EE (1) EE200100145A (fr)
ES (1) ES2252960T3 (fr)
GE (1) GEP20033025B (fr)
GT (1) GT199900146A (fr)
HK (1) HK1040396A1 (fr)
HN (1) HN1999000149A (fr)
HR (1) HRP20010167A2 (fr)
HU (1) HUP0103542A3 (fr)
ID (1) ID29129A (fr)
IL (1) IL141506A0 (fr)
IS (1) IS5860A (fr)
MA (1) MA26686A1 (fr)
NO (1) NO20011183L (fr)
NZ (1) NZ509841A (fr)
OA (1) OA11648A (fr)
PA (1) PA8481301A1 (fr)
PE (1) PE20001053A1 (fr)
PL (1) PL346648A1 (fr)
SK (1) SK3032001A3 (fr)
SV (1) SV1999000147A (fr)
TN (1) TNSN99169A1 (fr)
TR (1) TR200100694T2 (fr)
WO (1) WO2000014066A1 (fr)
YU (1) YU11501A (fr)
ZA (1) ZA200101744B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP1038872A1 (fr) 1999-02-22 2000-09-27 Pfizer Products Inc. Dérivés de 4-phényl-4-hétéroarylpiperdine comme ligands des récepteurs opioides
SE9902765D0 (sv) * 1999-07-21 1999-07-21 Astra Pharma Prod Novel compounds
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
EP1279666A1 (fr) 2001-07-24 2003-01-29 Pfizer Products Inc. Dérivés de 1-diphenylméthyl-pyrazoles comme ligands des récepteurs opioides
AU2003210916B9 (en) * 2002-02-07 2008-12-18 The Curators Of The University Of Missouri Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203301D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
BR0316521A (pt) 2002-11-26 2005-10-04 Pfizer Prod Inc Ativadores de ppar
EP2368553B1 (fr) 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Formulations pharmaceutiques contenant de la methylnaltrexone
AR044010A1 (es) * 2003-04-11 2005-08-24 Janssen Pharmaceutica Nv Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica
US20070078120A1 (en) * 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
WO2005061463A1 (fr) 2003-12-23 2005-07-07 Astex Therapeutics Limited Derives de pyrazole servant de modulateurs de proteine kinase
EP1584335A3 (fr) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Combinaison de substances actives comprenant un composé carbinol et un opioïde
US7872023B2 (en) * 2005-02-17 2011-01-18 Research Triangle Institute Kappa opioid receptor ligands
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
WO2006136823A1 (fr) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Amine contenant des heterocycliques comme inhibiteurs des kinases b
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
JP5345842B2 (ja) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
DE102005061427A1 (de) * 2005-12-22 2007-06-28 Grünenthal GmbH Substituierte Oxadiazol-Derivate
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
EP3263571B2 (fr) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Forme cristalline de bromure de (r)-n-methylnaltrexone et utilisations associées
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
CN101959892B (zh) * 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
EP2263664A1 (fr) * 2009-05-18 2010-12-22 Nestec S.A. Composé (thymoquinone, Nigella sativa) stimulant les récepteurs opioïdes et allergie alimentaire
JP7149961B2 (ja) 2017-01-17 2022-10-07 メビアス ディスカバリー インコーポレイテッド 置換３－ジアルキルアミノメチル－ピペリジン－４－イル－ベンズアミドならびにその作製方法および使用方法
US11584765B2 (en) 2017-03-12 2023-02-21 Ecstasy LLC Polycyclic amines as sigma receptor modulators
WO2018169818A1 (fr) * 2017-03-12 2018-09-20 Xiaodong Wang Amines polycycliques utilisées comme modulateurs des récepteurs opioïdes
US20190110804A1 (en) * 2017-10-16 2019-04-18 Michael Bruce Horowitz Catheter based retrieval device with proximal body having axial freedom of movement
AU2021300217A1 (en) 2020-07-01 2023-02-02 Ecstasy, LLC Polycyclic amines for opioid receptor modulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016280A (en) 1969-07-17 1977-04-05 Byk Gulden Lomberg Chemische Fabrik Gmbh 4,4-Diarylpiperidine compositions and use
DE1936452C3 (de) * 1969-07-17 1975-06-19 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenylpiperidlnen
DE2139084C3 (de) 1971-08-04 1979-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
DE2166997C3 (de) 1971-08-04 1980-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
DE2139085C3 (de) * 1971-08-04 1979-01-18 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Halogenierte 4,4-Diphenyl-piperidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
ES2066721B1 (es) * 1993-05-18 1996-02-16 Ferrer Int Nuevos compuestos derivados de la piridina 1,4-disustituida.
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
WO1996031208A2 (fr) * 1995-04-05 1996-10-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Utilisation de composes de piperidine ou de pyrrolidine substitues pour le traitement de maladies modulees par un recepteur sigma
WO1997042956A1 (fr) 1996-05-16 1997-11-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines et leurs emplois
EP0918767A4 (fr) 1996-05-31 2000-04-26 Allelix Neuroscience Inc Produit pharmaceutique pour le traitement de troubles neurologiques et neuropsychiatriques

Also Published As

Publication number Publication date
IL141506A0 (en) 2002-03-10
CA2343236A1 (fr) 2000-03-16
AU749096B2 (en) 2002-06-20
ZA200101744B (en) 2002-06-03
US20040138220A1 (en) 2004-07-15
HUP0103542A2 (hu) 2002-01-28
TR200100694T2 (tr) 2001-10-22
NZ509841A (en) 2003-08-29
EE200100145A (et) 2002-06-17
HUP0103542A3 (en) 2002-11-28
GT199900146A (es) 2001-02-24
NO20011183D0 (no) 2001-03-08
US20020013321A1 (en) 2002-01-31
PL346648A1 (en) 2002-02-25
PA8481301A1 (es) 2000-09-29
CZ2001850A3 (cs) 2001-12-12
DE69928945D1 (de) 2006-01-19
BG105411A (bg) 2001-12-29
SK3032001A3 (en) 2002-04-04
PE20001053A1 (es) 2000-10-14
KR20010075024A (ko) 2001-08-09
JP2002524445A (ja) 2002-08-06
AU5383799A (en) 2000-03-27
TNSN99169A1 (fr) 2005-11-10
IS5860A (is) 2001-02-23
SV1999000147A (es) 2000-09-06
EP1112255A1 (fr) 2001-07-04
ES2252960T3 (es) 2006-05-16
GEP20033025B (en) 2003-07-25
BR9913512A (pt) 2001-06-05
OA11648A (en) 2004-12-08
EA200100203A1 (ru) 2001-08-27
AP2001002088A0 (en) 2001-03-31
ATE312819T1 (de) 2005-12-15
HN1999000149A (es) 2000-01-12
CA2343236C (fr) 2006-01-03
HRP20010167A2 (en) 2002-02-28
ID29129A (id) 2001-08-02
HK1040396A1 (zh) 2002-06-07
US6720336B2 (en) 2004-04-13
CO5170416A1 (es) 2002-06-27
WO2000014066A1 (fr) 2000-03-16
EP1112255B1 (fr) 2005-12-14
DE69928945T2 (de) 2006-07-27
YU11501A (sh) 2003-10-31
CN1316993A (zh) 2001-10-10
AR022376A1 (es) 2002-09-04
MA26686A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
NO20011183D0 (no) 4,4-biarylpiperidinderivater med opoid reseptoraktivitet
NO20004787L (no) Indolderivater med antiviral aktivitet
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
ATE293618T1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
ATE340176T1 (de) Substituierte 6,5-heterobicyclische-derivate
DK0925298T3 (da) Substituerede 6,6-heterobicykliske derivater
ATE226212T1 (de) 2-(purin-9-)-tetrahydrofuran-3,4-diol-derivate
PT818454E (pt) Derivados de benzimidazole com actividade anti-histaminica
ATE231847T1 (de) Substituierte 1,2,3,4- tetrahydronaphthalinderivate
DE69821009D1 (de) 6,9-verbrückte erythromycin-derivate
ATE239750T1 (de) 6,11-verbrückte erythromycinderivate
ATE246199T1 (de) 3-descladinose-2,3-anhydroerythromycin-derivate
EE200000447A (et) 1,3,4-oksadiasolooni derivaadid
DE69933135D1 (de) Benzimidazolderivate mit vitronectinrezeptor-antagonistischer wirkung
ATE204279T1 (de) Diaza-spiro(3,5)nonan-derivate
DK1129079T3 (da) 2,4-disubstituerede triazinderivater med anti-HIV aktivitet
PT1010699E (pt) Derivados de 3-oxadiazolil-1,6-naftiridina-2(h)-ona substituido em 5
NO20015397D0 (no) 1,5-Benzodiazepin-derivater
DK1140830T3 (da) Arylpiperidin- og aryl-1,2,5,6-tetrahydropyridinamidderivater med 5HT1A receptoraktivitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application